Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
90% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MNTA: No Debt )
MNTA' s 10-Year Cash to Debt Range
Min: 10.74   Max: No Debt
Current: No Debt

Equity to Asset 0.83
MNTA's Equity to Asset is ranked higher than
89% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MNTA: 0.83 )
MNTA' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.96
Current: 0.83

-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
78% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. MNTA: No Debt )
MNTA' s 10-Year Interest Coverage Range
Min: 110.84   Max: 9999.99
Current: No Debt

110.84
9999.99
F-Score: 4
Z-Score: 6.63
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -259.22
MNTA's Operating margin (%) is ranked lower than
51% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. MNTA: -259.22 )
MNTA' s 10-Year Operating margin (%) Range
Min: -548.56   Max: 63.48
Current: -259.22

-548.56
63.48
Net-margin (%) -257.14
MNTA's Net-margin (%) is ranked lower than
51% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MNTA: -257.14 )
MNTA' s 10-Year Net-margin (%) Range
Min: -546.42   Max: 63.71
Current: -257.14

-546.42
63.71
ROE (%) -45.46
MNTA's ROE (%) is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MNTA: -45.46 )
MNTA' s 10-Year ROE (%) Range
Min: -66.11   Max: 59.21
Current: -45.46

-66.11
59.21
ROA (%) -38.56
MNTA's ROA (%) is ranked higher than
52% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MNTA: -38.56 )
MNTA' s 10-Year ROA (%) Range
Min: -389.52   Max: 55.62
Current: -38.56

-389.52
55.62
ROC (Joel Greenblatt) (%) -453.80
MNTA's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. MNTA: -453.80 )
MNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1125.81   Max: 348.38
Current: -453.8

-1125.81
348.38
Revenue Growth (3Y)(%) -34.90
MNTA's Revenue Growth (3Y)(%) is ranked higher than
50% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MNTA: -34.90 )
MNTA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 138.6
Current: -34.9

0
138.6
» MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MNTA Guru Trades in Q4 2013

PRIMECAP Management 1,505,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2014

MNTA Guru Trades in Q1 2014

Steven Cohen 3,029,124 sh (New)
John Burbank 12,200 sh (New)
Paul Tudor Jones 29,800 sh (New)
Jim Simons 425,134 sh (New)
PRIMECAP Management 2,159,414 sh (+43.48%)
» More
Q2 2014

MNTA Guru Trades in Q2 2014

Jim Simons 540,251 sh (+27.08%)
PRIMECAP Management 2,670,600 sh (+23.67%)
Steven Cohen 478,500 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

MNTA Guru Trades in Q3 2014

Steven Cohen 554,400 sh (+15.86%)
PRIMECAP Management 2,670,600 sh (unchged)
Jim Simons 366,351 sh (-32.19%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Add 23.67%0.01%$10.31 - $13.56 $ 11.881%2670600
John Burbank 2014-06-30 Sold Out $10.31 - $13.56 $ 11.881%0
PRIMECAP Management 2014-03-31 Add 43.48%0.01%$13.19 - $19.72 $ 11.88-30%2159414
John Burbank 2014-03-31 New Buy$13.19 - $19.72 $ 11.88-30%12200
Joel Greenblatt 2012-12-31 Sold Out 0.17%$10.32 - $14.82 $ 11.88-3%0
John Burbank 2012-09-30 Sold Out 0.07%$13.48 - $15.03 $ 11.88-16%0
Joel Greenblatt 2012-06-30 Add 502.05%0.13%$13.13 - $16.24 $ 11.88-19%156057
Richard Snow 2012-06-30 Sold Out 0.01%$13.13 - $16.24 $ 11.88-19%0
PRIMECAP Management 2012-06-30 Add 56.99%0.01%$13.13 - $16.24 $ 11.88-19%1039556
John Burbank 2012-03-31 New Buy0.08%$14.48 - $19.58 $ 11.88-22%150000
Joel Greenblatt 2012-03-31 Add 62.29%0.01%$14.48 - $19.58 $ 11.88-22%25921
Richard Snow 2011-12-31 Reduce -49.18%0.01%$11.02 - $17.49 $ 11.88-18%19810
Joel Greenblatt 2011-09-30 New Buy0.04%$10.62 - $20.92 $ 11.88-29%19658
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.13
MNTA's P/B is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. MNTA: 3.13 )
MNTA' s 10-Year P/B Range
Min: 1.34   Max: 14.92
Current: 3.13

1.34
14.92
P/S 13.93
MNTA's P/S is ranked higher than
57% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. MNTA: 13.93 )
MNTA' s 10-Year P/S Range
Min: 1.84   Max: 60.6
Current: 13.93

1.84
60.6
EV-to-EBIT -3.99
MNTA's EV-to-EBIT is ranked higher than
58% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. MNTA: -3.99 )
MNTA' s 10-Year EV-to-EBIT Range
Min: -52.2   Max: 17.4
Current: -3.99

-52.2
17.4
Current Ratio 10.25
MNTA's Current Ratio is ranked higher than
94% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MNTA: 10.25 )
MNTA' s 10-Year Current Ratio Range
Min: 4.39   Max: 28.87
Current: 10.25

4.39
28.87
Quick Ratio 10.25
MNTA's Quick Ratio is ranked higher than
95% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. MNTA: 10.25 )
MNTA' s 10-Year Quick Ratio Range
Min: 4.39   Max: 28.87
Current: 10.25

4.39
28.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.64
MNTA's Price/Net Cash is ranked higher than
96% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MNTA: 4.64 )
MNTA' s 10-Year Price/Net Cash Range
Min: 2.03   Max: 14.33
Current: 4.64

2.03
14.33
Price/Net Current Asset Value 4.45
MNTA's Price/Net Current Asset Value is ranked higher than
94% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MNTA: 4.45 )
MNTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.66   Max: 12.13
Current: 4.45

1.66
12.13
Price/Tangible Book 3.21
MNTA's Price/Tangible Book is ranked higher than
79% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. MNTA: 3.21 )
MNTA' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 10.14
Current: 3.21

1.5
10.14
Price/DCF (Projected) 6.95
MNTA's Price/DCF (Projected) is ranked higher than
78% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. MNTA: 6.95 )
MNTA' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 6.5
Current: 6.95

1.77
6.5
Price/Median PS Value 0.70
MNTA's Price/Median PS Value is ranked higher than
94% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. MNTA: 0.70 )
MNTA' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.7
Current: 0.7

0.09
2.7
Earnings Yield (Greenblatt) -25.10
MNTA's Earnings Yield (Greenblatt) is ranked lower than
52% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MNTA: -25.10 )
MNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.8   Max: 78
Current: -25.1

5.8
78

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 95 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 15 2014
Teva Upgraded On Strength Of Copaxone MS Drug Dec 12 2014
Momenta's Necuparanib Gets Fast Track Status in the U.S. Dec 02 2014
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment... Dec 01 2014
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment... Dec 01 2014
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a... Dec 01 2014
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a... Dec 01 2014
Insider Trading Alert - MNTA, DOC And DSCI Traded By Insiders Nov 28 2014
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST Nov 24 2014
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST Nov 24 2014
MOMENTA PHARMACEUTICALS INC Financials Nov 14 2014
10-Q for Momenta Pharmaceuticals, Inc. Nov 09 2014
MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences Nov 06 2014
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences Nov 06 2014
Momenta Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Nov 05 2014
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2014
Momenta misses 3Q profit forecasts Nov 05 2014
Momenta misses 3Q profit forecasts Nov 05 2014
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK